Granules India Limited
NSE: GRANULES BSE: GRANULES
NSE
529.95
-4.00 (-0.75%)
Prev Close
533.95
Open Price
534.05
Volume
485,798
Today Low / High
525.05 / 534.1
52 WK Low / High
422 / 721
Range
503 - 556
BSE
529.80
-4.10 (-0.77%)
Prev Close
533.9
Open Price
533.9
Volume
15,884
Today Low / High
525.2 / 533.9
52 WK Low / High
412.05 / 724.55
Range
503 - 556
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 529.95 (target range: 503 - 556), reflecting a change of -4 (-0.74913%). On the BSE, it is listed at 529.8 (target range: 503 - 556), showing a change of -4.1 (-0.76793%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
06 Jun
534.05
-0.77%
05 Jun
527.00
1.32%
04 Jun
525.50
0.35%
03 Jun
531.80
-1.94%
02 Jun
530.10
-0.18%
30 May
537.00
-1.20%
29 May
524.00
2.16%
28 May
530.00
-1.43%
27 May
520.10
1.67%
26 May
518.40
0.31%
23 May
515.05
0.56%
22 May
516.95
-0.15%
21 May
509.45
1.66%
20 May
512.70
-0.68%
19 May
505.00
1.33%
16 May
504.00
0.32%
15 May
493.00
1.92%
14 May
475.10
3.73%
13 May
460.15
3.82%
12 May
445.00
3.40%
09 May
432.00
2.06%
Granules India Limited Graph
Granules India Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Granules India Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 529.95, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 529.80 | 535.10 | 481.59 - 588.61 |
| 540.40 | 432.32 - 648.48 | ||
| 545.69 | 381.99 - 709.40 | ||
| Bearish Scenario | 529.80 | 524.50 | 472.05 - 576.95 |
| 519.20 | 415.36 - 623.04 | ||
| 513.91 | 359.73 - 668.08 |
Overview of Granules India Limited
ISIN
INE101D01020
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
1,158,283
Market Cap
128,536,192,800
Last Dividend
1.5
Official Website
IPO Date
2005-06-20
DCF Diff
-294.47
DCF
824
Financial Ratios Every Investor Needs
Stock Dividend of GRANULES
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-07-31 | July 31, 25 | 1.5 | 1.5 | 2025-07-31 | 2025-09-06 | |
| 2024-07-30 | July 30, 24 | 1.5 | 1.5 | 2024-07-30 | 2024-09-05 | |
| 2023-08-03 | August 03, 23 | 1.5 | 1.5 | 2023-08-03 | 2023-09-08 | |
| 2022-07-19 | July 19, 22 | 0.75 | 0.75 | 2022-07-20 | 2022-08-25 | |
| 2022-02-17 | February 17, 22 | 0.25 | 0.25 | 2022-02-18 | 2022-03-10 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 4,506.37 Cr | 2,130.71 Cr | 2,375.66 Cr | 0.5272 | 198.56 Cr | 85.13 Cr | 652.83 Cr | 405.31 Cr | 16.73 | 826.32 Cr | 0.0899 |
| 2023-03-31 | 4,511.92 Cr | 2,307.29 Cr | 2,204.63 Cr | 0.4886 | 116.38 Cr | 73.88 Cr | 782.04 Cr | 516.60 Cr | 21.05 | 927.60 Cr | 0.1145 |
| 2022-03-31 | 3,727.17 Cr | 1,958.90 Cr | 1,768.27 Cr | 0.4744 | 142.96 Cr | 51.44 Cr | 574.62 Cr | 412.76 Cr | 16.65 | 739.84 Cr | 0.1107 |
| 2021-03-31 | 3,196.03 Cr | 1,455.00 Cr | 1,741.03 Cr | 0.5447 | 100.16 Cr | 37.56 Cr | 727.57 Cr | 549.46 Cr | 22.05 | 882.11 Cr | 0.1719 |
| 2020-03-31 | 2,545.24 Cr | 1,315.56 Cr | 1,229.68 Cr | 0.4831 | 78.91 Cr | 33.98 Cr | 481.31 Cr | 335.40 Cr | 13.19 | 589.61 Cr | 0.1318 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 381.10 Cr | 5,520.98 Cr | 2,295.44 Cr | 3,225.5440 Cr | 1,315.06 Cr | 933.96 Cr | 1,300.55 Cr | 2,259.78 Cr | 17.84 Cr | 0.00 Cr | 21.52 Cr | 2,082.2930 Cr |
| 2023-03-31 | 291.56 Cr | 4,904.56 Cr | 2,069.66 Cr | 2,834.9090 Cr | 1,136.24 Cr | 844.68 Cr | 1,149.41 Cr | 1,859.36 Cr | 6.40 Cr | 0.00 Cr | 11.66 Cr | 1,813.5010 Cr |
| 2022-03-31 | 184.71 Cr | 4,512.90 Cr | 1,925.81 Cr | 2,586.5329 Cr | 1,106.31 Cr | 921.60 Cr | 978.55 Cr | 1,595.64 Cr | 6.61 Cr | 0.00 Cr | -195.04 Cr | 1,641.6000 Cr |
| 2021-03-31 | 41.84 Cr | 3,713.45 Cr | 1,540.18 Cr | 2,173.2743 Cr | 849.21 Cr | 807.37 Cr | 782.18 Cr | 1,255.99 Cr | 117.07 Cr | 0.00 Cr | -202.43 Cr | 1,173.0981 Cr |
| 2020-03-31 | 185.93 Cr | 3,301.50 Cr | 1,457.78 Cr | 1,843.7241 Cr | 892.10 Cr | 706.17 Cr | 438.43 Cr | 1,136.84 Cr | 61.01 Cr | 0.00 Cr | -32.60 Cr | 966.5405 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 439.4140 Cr | -360.1600 Cr | 7.6640 Cr | 58.8380 Cr | 89.5430 Cr | 381.1000 Cr | -380.5760 Cr | 405.3100 Cr | 154.7780 Cr | -36.3060 Cr | -140.7300 Cr |
| 2023-03-31 | 663.6780 Cr | -96.4520 Cr | -519.4700 Cr | 451.8850 Cr | 47.5030 Cr | 181.7460 Cr | -211.7930 Cr | 663.9400 Cr | -47.0920 Cr | -18.6220 Cr | -2.6700 Cr |
| 2022-03-31 | 332.0541 Cr | -380.1149 Cr | 189.9971 Cr | -65.6528 Cr | 142.8775 Cr | 184.7134 Cr | -397.7069 Cr | 557.9983 Cr | 253.0410 Cr | -37.1713 Cr | -184.0266 Cr |
| 2021-03-31 | 432.4778 Cr | -277.1350 Cr | -299.3131 Cr | 161.1362 Cr | -144.0930 Cr | 41.8359 Cr | -271.3416 Cr | 704.3643 Cr | -71.9332 Cr | -24.7208 Cr | -345.8876 Cr |
| 2020-03-31 | 476.1884 Cr | -160.6331 Cr | -212.8550 Cr | 291.7094 Cr | 102.9046 Cr | 185.9289 Cr | -184.4790 Cr | 425.6352 Cr | -153.3990 Cr | -30.6509 Cr | -54.2183 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 1,133.52 Cr | 435.68 Cr | 697.84 Cr | 0.6156 | 173.68 Cr | 117.60 Cr | 4.85 | 235.97 Cr | 0.1038 |
| 2024-09-30 | 956.52 Cr | 367.21 Cr | 589.32 Cr | 0.6161 | 150.80 Cr | 97.23 Cr | 4.01 | 206.57 Cr | 0.1017 |
| 2024-06-30 | 1,179.87 Cr | 700.92 Cr | 478.95 Cr | 0.4059 | 206.40 Cr | 134.65 Cr | 5.56 | 261.33 Cr | 0.1141 |
| 2024-03-31 | 1,175.78 Cr | 674.48 Cr | 501.30 Cr | 0.4264 | 202.53 Cr | 129.65 Cr | 5.35 | 257.58 Cr | 0.1103 |
| 2023-12-31 | 1,155.58 Cr | 497.33 Cr | 658.25 Cr | 0.5696 | 198.74 Cr | 125.65 Cr | 5.18 | 251.13 Cr | 0.1087 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 208.85 Cr | 9.71 Cr | 218.56 Cr | 0.00 Cr | 1,395.44 Cr | 2,605.34 Cr | 2,304.37 Cr | 5,432.70 Cr | 2,005.47 Cr |
| 2024-06-30 | -381.10 Cr | 762.20 Cr | 381.10 Cr | 0.00 Cr | 0.00 Cr | 381.10 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 386.39 Cr | 8.19 Cr | 386.39 Cr | 1,001.88 Cr | 1,300.55 Cr | 2,905.05 Cr | 2,115.63 Cr | 5,520.98 Cr | 2,295.44 Cr |
| 2023-12-31 | -311.91 Cr | 623.81 Cr | 311.91 Cr | 0.00 Cr | 0.00 Cr | 311.91 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 295.50 Cr | 18.66 Cr | 314.16 Cr | 1,015.73 Cr | 1,279.61 Cr | 2,792.31 Cr | 2,006.52 Cr | 5,264.85 Cr | 2,297.44 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 134.65 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 129.65 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 125.65 Cr | 104.78 Cr | 0.00 Cr | 0.00 Cr | 104.78 Cr | 416.69 Cr | 311.91 Cr | 0.00 Cr | 104.78 Cr |
| 2023-09-30 | 102.12 Cr | 105.05 Cr | 0.00 Cr | 0.00 Cr | 105.05 Cr | 311.91 Cr | 206.86 Cr | 0.00 Cr | 105.05 Cr |
| 2023-06-30 | 47.90 Cr | 98.48 Cr | 0.00 Cr | 0.00 Cr | 98.48 Cr | 411.27 Cr | 312.79 Cr | 0.00 Cr | 98.48 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2015-03-23 | March 23, 15 | 10:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,679.20 | ₹4,028,870,976,000.00 | ₹2,500,031.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,544.50 | ₹1,737,361,870,500.00 | ₹361,018.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,320.90 | ₹1,100,458,988,118.00 | ₹2,158,463.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,154.30 | ₹1,067,557,063,500.00 | ₹86,576.00 |
| Mankind Pharma Limited | MANKIND | ₹2,352.40 | ₹970,767,378,020.00 | ₹353,197.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹960.15 | ₹966,131,734,500.00 | ₹810,089.00 |
| Lupin Limited | LUPIN | ₹1,999.60 | ₹913,207,322,000.00 | ₹1,289,535.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,161.10 | ₹674,369,202,200.00 | ₹392,642.00 |
| Alkem Laboratories Limited | ALKEM | ₹4,862.50 | ₹581,384,812,500.00 | ₹181,782.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,590.20 | ₹448,756,030,200.00 | ₹940,265.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹1,055.10 | ₹403,646,450,141.00 | ₹209,681.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,370.90 | ₹347,802,813,600.00 | ₹594,702.00 |
| Laurus Labs Limited | LAURUSLABS | ₹642.05 | ₹346,227,388,650.00 | ₹1,658,718.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,571.30 | ₹321,186,225,600.00 | ₹84,218.00 |
| Piramal Enterprises Limited | PEL | ₹1,173.70 | ₹266,051,968,600.00 | ₹1,087,297.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,702.30 | ₹265,322,180,300.00 | ₹62,791.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,790.00 | ₹244,750,000,000.00 | ₹123,199.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,505.40 | ₹244,595,886,600.00 | ₹803,276.00 |
| Eris Lifesciences Limited | ERIS | ₹1,638.30 | ₹223,111,885,500.00 | ₹55,563.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹987.60 | ₹194,125,618,800.00 | ₹40,498.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,140.00 | ₹181,580,340,000.00 | ₹116,733.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,030.00 | ₹167,173,597,000.00 | ₹539,376.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,093.30 | ₹159,115,291,610.00 | ₹64,315.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹858.30 | ₹153,730,113,000.00 | ₹354,578.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹529.95 | ₹128,536,192,800.00 | ₹485,798.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,560.50 | ₹92,300,963,700.00 | ₹8,096.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹914.45 | ₹89,424,888,505.00 | ₹310,698.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹909.25 | ₹82,409,528,235.00 | ₹242,116.00 |
| Strides Pharma Science Limited | STAR | ₹782.30 | ₹72,098,880,210.00 | ₹430,298.00 |
| FDC Limited | FDC | ₹429.20 | ₹69,878,052,000.00 | ₹308,089.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹165.55 | ₹53,724,617,100.00 | ₹2,347,837.00 |
| Innova Captab Limited | INNOVACAP | ₹889.10 | ₹50,878,685,263.00 | ₹72,505.00 |
| Suven Life Sciences Limited | SUVEN | ₹221.19 | ₹48,235,788,060.00 | ₹1,475,325.00 |
| Sequent Scientific Limited | SEQUENT | ₹187.85 | ₹47,019,230,700.00 | ₹442,806.00 |
| Hikal Limited | HIKAL | ₹372.35 | ₹45,911,127,350.00 | ₹154,610.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹462.15 | ₹42,180,430,500.00 | ₹112,178.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹592.90 | ₹41,743,598,820.00 | ₹18,878.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹368.10 | ₹36,912,331,800.00 | ₹50,918.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹718.15 | ₹36,423,921,665.00 | ₹149,821.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,141.70 | ₹35,421,576,300.00 | ₹12,390.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹64.12 | ₹35,134,810,480.00 | ₹2,840,731.00 |
| Alembic Limited | ALEMBICLTD | ₹112.07 | ₹28,777,558,628.00 | ₹591,652.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹88.74 | ₹26,047,585,980.00 | ₹1,118,303.00 |
| Indoco Remedies Limited | INDOCO | ₹275.10 | ₹25,377,397,290.00 | ₹25,198.00 |
Key Executives
Chief Technology Officer
Dr. P. V. Srinivas
Gender: Not Specified
Year Born: 1966
Chief Human Resources Officer
Mr. Atul Dhavle B.E.
Gender: male
Year Born: 1970
Chairman & MD
Dr. Krishna Prasad Chigurupati B.Sc.
Gender: Not Specified
Year Born: 1954
Company Secretary & Compliance Officer
Ms. Chaitanya Tummala
Gender: female
Year Born:
Chief Financial Officer
Mr. Mukesh Surana
Gender: male
Year Born: 1981
Joint MD, Chief Executive Officer & Additional Director
Dr. Kandiraju Venkata Sita Ram Rao B.Tech, M.E., Ph.D.
Gender: Not Specified
Year Born: 1963
President and Chief Strategy & Sustainability Officer
Mr. Sanjay Kumar
Gender: male
Year Born:
Whole-Time Director
Ms. Priyanka Chigurupati
Gender: female
Year Born:
Executive Director
Mr. Harsha Chigurupati BBA
Gender: male
Year Born: 1983
President & Head - Formulations Operations
Mr. Ramraj Rangarajulu
Gender: male
Year Born:
FAQs about Granules India Limited
Who is the CEO of the company?
The CEO is Dr. Kandiraju Venkata Sita Ram Rao B.Tech, M.E., Ph.D..
What is the current market price of the stock?
The current price is ₹529.95.
What is the 52-week price range?
The range is ₹422-721.
What is the market capitalization of the company?
The market capitalization is ₹12,853.62 crores.
What is the dividend yield?
The dividend yield is 0.28%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 26.82.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Granules India Limited (ISIN: INE101D01020) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹12,853.62 crores and an average daily volume of 1,158,283 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹1.5.